Towards host-directed therapies for tuberculosis

Alimuddin Zumla, Markus Maeurer, Jeremiah Chakaya, Michael Hoelscher, Francine Ntoumi, Roxana Rustomjee, Cristina Vilaplana, Dorothy Yeboah-Manu, Voahangy Rasolof, Paula Munderi, Nalini Singh, Eleni Aklillu, Nesri Padayatchi, Eusebio Macete, Nathan Kapata, Modest Mulenga, Gibson Kibiki, Sayoki Mfinanga, Thomas Nyirenda, Leonard MabokoAlberto Garcia-Basteiro, Niaina Rakotosamimanana, Matthew Bates, Peter Mwaba, Klaus Reither, Sebastien Gagneux, Sarah Edwards, Elirehema Mfinanga, Salim Abdulla, Pere-Joan Cardona, James B. W. Russell, Vanya Gant, Mahdad Noursadeghi, Paul Elkington, Maryline Bonnet, Clara Menendez, Tandakha N. Dieye, Bassirou Diarra, Almoustapha Maiga, Abraham Aseffa, Shreemanta Parida, Christian Wejse, Eskild Petersen, Pontiano Kaleebu, Matt Oliver, Gill Craig, Tumena Corrah, Leopold Tientcheu, Martin Antonio, Martin Rao, Timothy D. McHugh, Aziz Sheikh, Giuseppe Ippolito, Gita Ramjee, Stefan H. E. Kaufmann, Gavin Churchyard, Andrie Steyn, Martin Grobusch, Ian Sanne, Neil Martinson, Rajhmun Madansein, Robert J. Wilkinson, Bongani Mayosi, Marco Schito, Robert S. Wallis

Research output: Contribution to journalEditorialAcademicpeer-review

100 Citations (Scopus)

Abstract

The treatment of tuberculosis is based on combinations of drugs that directly target Mycobacterium tuberculosis. A new global initiative is now focusing on a complementary approach of developing adjunct host-directed therapies
Original languageEnglish
Pages (from-to)511-512
JournalNature reviews. Drug discovery
Volume14
Issue number8
DOIs
Publication statusPublished - 2015

Cite this